Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | PGR | P06401 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 3/20 | 0.64 |
| ▸ | PKLR | P30613 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021987 | 0.86 | PGR (0.77) | ATMPGRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL29549847 | 0.86 | PGR (0.77) | ATMPGRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL28396503 | 0.86 | PGR (0.77) | ATMPGRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL9479593 | 0.84 | PGR (0.73) | ATMPGRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL9942088 | 0.84 | ATM (0.72) | ATMPGRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL808105 | 0.84 | ATM (0.72) | ATMPGRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL8752432 | 0.81 | PLAU (0.76) | ATMPGRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL27790749 | 0.81 | ATM (0.73) | ATMPGRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL15480550 | 0.81 | LMNA (0.73) | ATMPGRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL9942091 | 0.81 | ATM (0.68) | ATMPGRSMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | LDLR, APOB, NR1H2 | ATM 2000/4885PGR 2048/4885SMN1; SMN2 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.